WISE sets a new frontier for product complexity by shifting the focus from geometry to functionality, introducing features such as self-healing, triggered biomolecule diffusion, and smart repairing. This disruption redefines current design methodology, leveraging advanced AI-aided engineering and multi-scale, multi-process manufacturing to achieve unprecedented complexity. WISE has the potential to drive a discontinuity in the growth of the European industry by convincingly demonstrating an innovative, competitive, and scalable manufacturing concept based on a single machine that integrates macroscale processing (i.e., DED via hybrid blue-IR lasers) and micro-nano scale processing (i.e., fs and ns laser ablation, 2PP, DALP). WISE will deliver a TRL7 multi-process machine integrating high-precision, multi-scale techniques for producing complex multifunctional products. The project will demonstrate the machine's performance, flexibility, and precision by producing three complex hybrid products in MedTech, Aerospace, and Power generation sectors. The project builds upon TRL5-validated results from previous H2020 projects, which have brought significant innovations in the field of advanced manufacturing and enabling technologies. The work plan includes a final demonstration to validate the solution through the production of complex components based on end-user requirements. Upon completion, WISE will be further developed to reach TRL9 within 24 months, leading to its commercial launch as a multi-process manufacturing station. The WISE consortium is composed of 16 partners, including 8 SMEs, 4 LE, and 4 RTD. Their expertise covers mechatronics, intelligent nanostructured components, laser-material interaction, high-precision machines and tools. The project partners form a cluster of European countries playing crucial roles in the production of functionalized products with smart functionalities, adaptive photonic solutions, and advanced mechatronic systems.

The catastrophic ongoing pandemic has attracted our attention towards the spread of harmful pathogens facilitated by high traffic surfaces, highlighting the importance and urgency of an economically and environmentally sustainable solution for antimicrobial surface as a potential strategy to mitigate the spread of disease outbreaks. Nanoparticle (NP) filled coatings, with recognised effectiveness against bacteria, viruses, and fungi, are valuable candidates for developing antimicrobial surface and minimising the surface adhesion of pathogens. However, due to the many technical challenges, including difficulty to develop nanocoatings with a long-term antimicrobial capability, durability under real conditions and safety assurance, their application at industrial level is still limited. The SUPREME consortium will develop a platform of efficient and multifunctional antimicrobial nanocoatings, building upon bespoke TiO2 nanoparticles that have demonstrated an exceptional antimicrobial ability at lab scale (TRL3). Two sustainable routes: 1) customised core/shell and advanced functional nanoparticles and 2) hybrid fibre-nanoparticles (using sustainable bio-based cellulose materials and nanoparticles) will be pursued. Bearing in mind the specific requirements of individual applications, the SUPREME consortium will coordinate the antimicrobial testings to its effectiveness against a wide range of pathogens. The production of the SUPREME coating will follow a sustainable-by-design approach that considers both toxicity and environmental impact from outset to guarantee both market acceptance and sustainability of the overall process whilst having a robust safety assurance in place for human health. The scaling-up production of these sustainable materials and their validation according to the industrial requirements will enable to reach the TRL6 by the end of the project.